Navigation Links
Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

DALLAS, Feb. 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, Chairman and CEO of Access, is scheduled to deliver a presentation about the company at the 10th Annual BIO CEO & Investor Conference on February 13, 2008 at 12:30 pm Eastern Time. The conference will take place February 11-13, 2008 in New York City at the Waldorf Astoria Hotel.

The presentation will be webcast live via the Company's web site at http://www.accesspharma.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-KSB and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
2. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
3. Access Pharmaceuticals Announces $2.7 Million New Equity
4. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
5. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
6. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
7. Access Pharmaceuticals Announces $19.5 Million Recapitalization
8. Access Genetics Announces New Executive Appointments
9. Pharmasset Accesses up to $30 Million of Working Capital
10. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
11. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... YORK , May 26, 2016 ... today that it will be a featured presenter at the ... in New York City at the ... Denis Corin , Q BioMed Inc. CEO, is scheduled to ... will cover the company,s business strategy, recent developments and outline ...
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
(Date:5/25/2016)... ... ... at the University of Athens say they have evidence that the variety of different ... lead to one good one. Surviving Mesothelioma has just posted an article on the ... 98 mesothelioma patients who got a second kind of drug therapy after ...
(Date:5/24/2016)... May 24, 2016   MedyMatch Technology Ltd ., the ... intelligence, real-time decision support tools in the emergency room, announced ... 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... 15th National Life Sciences and Technology Week, and ... Intercontinental Hotel in Tel Aviv, Israel . ...
Breaking Biology Technology:
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/15/2016)... --> --> ... Research "Digital Door Lock Systems Market - Global Industry Analysis, ... global digital door lock systems market in terms of revenue ... forecast to grow at a CAGR of 31.8% during the ... enterprises (MSMEs) across the world and high industrial activity driving ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):